Biovitrum
International pharmaceutical company that markets specialist pharmaceuticals in several regions globally.
Launch date
Employees
Company register number 556616-7317
Solna kommun Stockholm County (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 545m | 661m | 891m | 1.4b | 1.5b | 1.5b | 1.7b |
| % growth | 55 % | 21 % | 35 % | 53 % | 12 % | - | 11 % |
| EBITDA | 161m | 216m | 352m | 585m | 683m | 566m | 563m |
| % EBITDA margin | 30 % | 33 % | 39 % | 43 % | 45 % | 37 % | 33 % |
| Profit | 84.7m | 117m | 236m | 316m | 323m | 262m | 237m |
| % profit margin | 16 % | 18 % | 26 % | 23 % | 21 % | 17 % | 14 % |
| EV / revenue | 5.5x | 4.5x | 5.5x | 4.5x | 4.5x | 4.3x | 4.0x |
| EV / EBITDA | 18.6x | 13.7x | 13.9x | 10.6x | 9.9x | 11.5x | 11.9x |
| R&D budget | 81.0m | 91.6m | 105m | 136m | 158m | 193m | 209m |
| R&D % of revenue | 15 % | 14 % | 12 % | 10 % | 10 % | 13 % | 12 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Early VC | ||
N/A | Acquisition | ||
| Total Funding | - | ||